BIOA: BioAmber Inc. - Summary | Jitta

BioAmber Inc.

NYSE:BIOA

Price
$22.32
Loss Chance
57.9%
1.13JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
430 / 713
3,144 / 4,222
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (15)
Recent Business Performance (56)
Financial Strength (29)
Return to Shareholders (0)
Competitive Advantage (16)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 45.66% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
1.13
100.00%
3.05
215.73%
3.05
149.75%
Pharmaceuticals
4.95
54.19%
5.05
82.51%
5.69
90.01%
COMPANY DESCRIPTION
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.